MNMD Stock Price, Mind Medicine Quote, Chart

Market Summary

USD8.54-0.14

Delayedas of 22 Apr 2024, 01:07 pm

-1.61%

MNMD Alerts

1 major insider sales recently.

MNMD Stock Price

View Fullscreen

MNMD RSI Chart

MNMD Valuation

Market Cap

358.8M

Price/Earnings (Trailing)

-3.75

EV/EBITDA

-2.34

Price/Free Cashflow

-5.57

MarketCap/EBT

-3.89

MNMD Price/Earnings (Trailing)

MNMD Profitability

Return on Equity

-122.52%

Return on Assets

-76.87%

Free Cashflow Yield

-17.94%

MNMD Fundamentals

MNMD Earnings

Earnings (TTM)

-95.7M

Earnings Growth (Yr)

-386.72%

Earnings Growth (Qtr)

-33.15%

Breaking Down MNMD Revenue

52 Week Range

2.918.68

(Low)(High)

Last 7 days

-10.1%

Last 30 days

-12.0%

Last 90 days

142.1%

Trailing 12 Months

128.1%

How does MNMD drawdown profile look like?

MNMD Financial Health

Current Ratio

3.22

MNMD Investor Care

Shares Dilution (1Y)

8.83%

Diluted EPS (TTM)

-2.44

Tracking the Latest Insider Buys and Sells of Mind Medicine

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 25, 2024	karlin dan	sold	-62,491	9.5	-6,578	chief medical officer
Mar 25, 2024	greenway schond l.	sold (taxes)	-54,376	9.78	-5,560	chief financial officer
Mar 25, 2024	barrow robert	sold	-156,930	9.5	-16,519	chief executive officer
Dec 26, 2023	barrow robert	sold	-48,050	3.63	-13,237	chief executive officer
Dec 26, 2023	karlin dan	sold	-24,589	3.63	-6,774	chief medical officer
Dec 26, 2023	greenway schond l.	sold	-20,516	3.63	-5,652	chief financial officer
Sep 25, 2023	karlin dan	sold	-24,729	3.57468	-6,918	chief medical officer
Sep 25, 2023	barrow robert	sold	-48,273	3.5761	-13,499	chief executive officer
Sep 25, 2023	greenway schond l.	sold	-20,608	3.57669	-5,762	chief financial officer
Aug 25, 2023	greenway schond l.	sold	-76,000	3.8	-20,000	chief financial officer

Which funds bought or sold MNMD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	SJS Investment Consulting Inc.	reduced	-14.29	61.00	113	-%
Apr 18, 2024	Hexagon Capital Partners LLC	unchanged	-	23.00	38.00	-%
Apr 16, 2024	TSFG, LLC	unchanged	-	-	-	-%
Apr 16, 2024	Robbins Farley	unchanged	-	161	264	-%
Apr 15, 2024	JANICZEK WEALTH MANAGEMENT, LLC	unchanged	-	57.00	94.00	-%
Apr 12, 2024	Pacifica Partners Inc.	unchanged	-	138	208	-%
Apr 12, 2024	AdvisorNet Financial, Inc	sold off	-100	-11.00	-	-%
Apr 11, 2024	Signature Resources Capital Management, LLC	unchanged	-	-	194	-%
Apr 09, 2024	American Capital Advisory, LLC	new	-	121	121	-%
Apr 05, 2024	NBC SECURITIES, INC.	new	-	5,000	5,000	-%

Are Funds Buying or Selling MNMD?

Are funds buying MNMD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MNMD

No. of Funds

MNMD Alerts

1 major insider sales recently.

Unveiling Mind Medicine's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 21, 2024	commodore capital lp	8.3%	5,833,333	SC 13G
Mar 15, 2024	deep track capital, lp	9.49%	6,666,667	SC 13G
Feb 14, 2023	cvi investments, inc.	4.9%	1,973,266	SC 13G/A
Oct 07, 2022	samberg joseph d	5.0%	1,915,000	SC 13G
Oct 06, 2022	cvi investments, inc.	5.6%	2e+06	SC 13G

Recent SEC filings of Mind Medicine

View All Filings

Date Filed	Form Type	Document
Apr 02, 2024	S-3	S-3
Apr 01, 2024	8-K	Current Report
Mar 26, 2024	4	Insider Trading
Mar 26, 2024	4	Insider Trading
Mar 26, 2024	4	Insider Trading
Mar 25, 2024	144	Notice of Insider Sale Intent
Mar 25, 2024	144	Notice of Insider Sale Intent
Mar 21, 2024	SC 13G	Major Ownership Report
Mar 18, 2024	D	D
Mar 15, 2024	SC 13G	Major Ownership Report

Mind Medicine News

Latest updates

Mind Medicine Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet										(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2020Q4
Assets	-12.0%	125	142	142	156	170	181	134	149	164	82.00
Current Assets	-13.5%	104	120	120	132	146	157	109	123	137	82.00
Cash Equivalents	-15.3%	100	118	117	129	142	155	106	120	134	80.00
Goodwill	0%	20.00	20.00	20.00	20.00	20.00	20.00	20.00	20.00	20.00	-
Liabilities	1.8%	46.00	46.00	36.00	25.00	19.00	27.00	10.00	12.00	12.00	6.00
Current Liabilities	3.5%	32.00	31.00	35.00	24.00	18.00	26.00	8.00	11.00	10.00	3.00
Shareholder's Equity	-18.6%	78.00	96.00	106	130	151	154	125	137	152	76.00
Retained Earnings	-9.0%	-290	-266	-248	-219	-194	-189	-173	-156	-137	-44.64
Additional Paid-In Capital	1.8%	368	362	354	349	345	342	297	292	288	120
Shares Outstanding	2.5%	41.00	40.00	39.00	38.00	38.00	29.00	28.00	28.00	28.00	18.00
Float	-	-	-	140	-	-	-	272	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Cashflow From Operations	-23.7%	-20,563	-16,626	-13,845	-13,331	-12,849	-9,297	-15,127	-12,866	-7,833	-16,782	-11,171	-10,038	-	-
Share Based Compensation	-13.0%	3,676	4,226	3,842	3,750	1,376	4,286	4,253	3,792	4,344	4,105	32,988	1,279	-	-
Cashflow From Investing	-	-	-	-	-	-	-	-	-	113	-27.00	-67.00	-316	-	-
Cashflow From Financing	-85.1%	2,593	17,398	1,274	583	416	58,211	590	-166	127	820	7,889	89,988	-	-

MNMD Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 52,124	$ 36,169
General and administrative	41,742	30,162
Total operating expenses	93,866	66,331
Loss from operations	(93,866)	(66,331)
Other income/(expense):
Interest income, net	4,664	1,495
Foreign exchange gain, net	157	195
Change in fair value of 2022 USD Financing Warrants	(6,636)	7,843
Other (expense)/income	(51)	2
Total other (expense)/income, net	(1,866)	9,535
Net loss	(95,732)	(56,796)
Other comprehensive loss:
Loss on foreign currency translation	(284)	(419)
Comprehensive loss	$ (96,016)	$ (57,215)
Net loss per common share, basic	$ (2.44)	$ (1.84)
Net loss per common share, diluted	$ (2.44)	$ (1.84)
Weighted-average common shares, basic	39,157,420	30,857,463
Weighted-average common shares, diluted	39,157,420	30,857,463

MNMD Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 99,704	$ 142,142
Prepaid and other current assets	4,168	3,913
Total current assets	103,872	146,055
Goodwill	19,918	19,918
Intangible assets, net	527	3,689
Other non-current assets	224	331
Total assets	124,541	169,993
Current liabilities:
Accounts payable	4,136	2,111
Accrued expenses	11,634	5,877
2022 USD Financing Warrants	16,476	9,904
Total current liabilities	32,246	17,892
Credit facility, long-term	14,129
Other liabilities, long-term	32	1,184
Total liabilities	46,407	19,076
Commitments and contingencies (Note 11)
Shareholders' Equity:
Common shares, no par value, unlimited authorized as of December 31, 2023 and 2022; 41,101,303 and 37,979,136 issued and outstanding as of December 31, 2023 and 2022, respectively
Additional paid-in capital	367,991	344,758
Accumulated other comprehensive income	343	627
Accumulated Deficit	(290,200)	(194,468)
Total shareholders' equity	78,134	150,917
Total liabilities and shareholders' equity	$ 124,541	$ 169,993

About Mind Medicine

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ÃƒÅ¸4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.

CEO	Mr. Robert Barrow
WEBSITE	mindmed.co
INDUSTRY	Biotechnology
EMPLOYEES	48

Mind Medicine Frequently Asked Questions

What is the ticker symbol for Mind Medicine? What does MNMD stand for in stocks?

MNMD is the stock ticker symbol of Mind Medicine. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Mind Medicine (MNMD)?

As of Fri Apr 19 2024, market cap of Mind Medicine is 358.78 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MNMD stock?

You can check MNMD's fair value in chart for subscribers.

What is the fair value of MNMD stock?

You can check MNMD's fair value in chart for subscribers. The fair value of Mind Medicine is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Mind Medicine is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MNMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Mind Medicine a good stock to buy?

The fair value guage provides a quick view whether MNMD is over valued or under valued. Whether Mind Medicine is cheap or expensive depends on the assumptions which impact Mind Medicine's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MNMD.